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Since  the  original  discovery  of idiotypes  (1-3),  their  structural  basis  and 
biological  significance  have  been  a  central  interest  in  immunology.  Recently, 
Bona et ai. (4) described a peculiar antiidiotypic antibody that reacted not only 
with an  idiotype on a  monoclonal,  human  anti-IgG  autoantibody (rheumatoid 
factor, RF), 1 but also with the Fc fragment of human  IgG (4).  They called this 
doubly reactive antiidiotype an epibody, i.e.,  an antibody recognizing  both an 
idiotope and an epitope on the original antigen. 
Very recently, we prepared and characterized three different types of antiidi- 
otypic antibodies against  human  rheumatoid  factors:  (a) a  monoclonal  antiidi- 
otype (mAb  17.109),  that  reacts  with  30%  of human  monoclonai  RF  (5);  (b) 
antiidiotype that  bears the  "internal  image"  of human  IgG,  and  thus  binds  to 
most human  RF (6);  and (c) antiidiotypes induced by synthetic peptides corre- 
sponding to distinct, complementarity-determining  regions (CDR) on RF heavy 
and  light  chains  (7,  8).  The  latter,  CDR  peptide-induced  antibodies  identify 
preselected idiotypes, with amino acid sequences homologous to the immunizing 
peptides. 
In  the  present  study,  we  describe  the  induction  of an  antiidiotype  against 
human  RF with  epibody properties.  Surprisingly,  the  epibody was elicited by 
immunization  with  a  synthetic  peptide.  The  results  provide  evidence  for  the 
possible molecular basis of the epibody phenomenon. 
Materials and Methods 
Preparation  of the Synthetic Peptide.  We synthesized a peptide, designated PGL 1, that 
corresponded to amino acid residues 23-34 (first CDR and Cys of the first  framework 
region) in  the light  chain  of the  monoclonal  IgM-RF Glo,  according to the sequence 
reported by Capra and Kehoe (9). It is composed of Cys-Arg-Ala-Ser-Gln-Ser-VaI-Ser-Ser- 
Ser-Tyr-Leu-Ala. 
The synthesis of the control peptide, PSH3 (corresponding to the third CDR of the 
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heavy chain of the IgM-RF Sie) has been described previously (7). It is composed of Glu- 
Trp-Lys-Gly-Gln-VaI-Asn-Vai-Asn-Pro-Phe-Asp-Tyr-Gly-Gly-Cys. 
Immunization of Animals.  The synthetic peptide PGL 1 was conjugated via its terminal 
cysteine to keyhold limpet haemocyanin (KLH) with M-maleimidobenzoyl N-hydroxysuc- 
cinamide ester, as described previously (10). Each of three rabbits was injected subcuta- 
neously with  5 mg of the conjugate, emulsified in complete Freund's adjuvant (CFA). 
The rabbits were boosted twice: 1 mg on day 30 and 2 mg on day 120. The rabbits were 
bled at various times and the anti-GIo antiidiotype activity was  monitored by enzyme- 
linked immunosorbent assay (ELISA). 
Purification of Proteins.  Plasma or purified proteins from patients with monoclonal 
IgM cryoglobulins were kindly provided by Drs. J.  D. Capra, G. Abraham, F.  Goni, B. 
Fragione, J. Johnson, and H. Metzger. The IgM cryoglobulins were purified as described 
previously (8). Pooled human IgG was prepared from Cohn fraction II (Sigma Chemical 
Co., St. Louis, MO) by DEAE cellulose chromatography in 0.01 M sodium phosphate, pH 
8.0. 
ELISA.  This was done exactly as described previously (7, 8). Briefly, antigens (2 #g/ 
ml) in 0.1  M borate, 0.2 M NaC1, pH 8.2 (BBS) were used to coat microtiter plates (3590; 
Costar, Data Packaging, Cambridge, MA) at 100 #l/well. After blocking with 1% bovine 
serum albumin (BSA),  100-#1 samples diluted in BBS containing 0.5% BSA were distrib- 
uted to duplicate wells. The plates were incubated for 3 h at room temperature, and the 
bound  antibodies  were  quantified  by  the  binding  of human  IgG-adsorbed,  alkaline 
phosphatase-labeled goat anti-rabbit  IgG (Kirkegaard & Perry Laboratories, Gaithers- 
burg, MD). 
Protein Blotting.  The reactivity of the anti-PGL1 antibody with immunogiobulin mol- 
ecules was analyzed by the immunoblot method (11, 12) with some modifications. Briefly, 
~ 10 #g of individual monoclonal IgM-RF proteins (5, 7, 13) or pooled human IgG, in 20 
#i sample buffer supplemented with 0.01% 2-mercaptoethanol, was loaded onto each slot 
of a  10%  polyacrylamide slab gel containing 0.1%  sodium dodecyl sulfate (14).  After 
electrophoresis (2.5 h at 30 mA), the proteins in the gel were transferred electrophoret- 
icaily to  nitrocellulose paper (2  h  at  70  V).  Protein-binding sites on  the  paper were 
quenched with 0.01 M phosphate-buffered saline (PBS), pH 7.2, containing 5% BSA, for 
1 h at room temperature. Subsequently, the paper was overlaid with anti-PGL1 antiserum 
for 1 h. After washing with BBS, the paper was developed with ~5I-labeled protein A (1 
mCi/mg, 2 ×  10  s cpm/mi) for another hour. After extensive washing with BBS, the paper 
was dried and finally exposed to Kodak XAR-5 film overnight at -70°C. 
Affinity Chromatography.  The globulin fraction of the rabbit antiserum, prepared by 
precipitation with a 33% saturated ammonium sulfate, was adsorbed sequentially with a 
BSA-Sepharose 4B column  (13.4  mg/ml  ×  1.5  ml) and  a  rabbit  IgG-Sepharose  4B 
column (8.3  mg/ml  ×  1 mi) to remove nonspecific binding material and any possible 
rabbit  RF  activity.  The  adsorbed  antibody  was  then  circulated over a  human  IgG- 
Sepharose 4B column (9.5 mg/mi × 2 ml). After removal of nonbound material with BBS, 
the bound antibody was eluted with 0.1  M glycine-hydrochloric acid, pH 2.5, and then 
was immediately neutralized with Tris base (Sigma Chemical Co.). 
Results 
Induction  of Anti-RF  Antibody  With  the  PGL1  Peptide.  After  receiving  two 
subcutaneous  injections of the  PGL1  peptide conjugated  to  KLH, the  rabbits 
were  bled,  and  their  sera  were  analyzed  for antipeptide  antibody activity  by 
ELISA. All three immunized rabbits produced anti-PGL 1 antibody. Two of the 
antisera reacted significantly with the corresponding intact IgM-RF Glo (Table 
1). 
Since IgM-RF Glo reacted with rabbit IgG, an immunoblot assay was used to 
demonstrate the  de facto antiidiotype activity of the anti-PGL1  antiserum  (7). 
IgM-RF  GIo  and  the  control,  pooled  human  IgG  (Cohn  fraction  II),  were CHEN,  FONG,  HOUGHTEN,  AND  CARSON 
TABLE  I 
Induction of Anti-RF Antibodies with PGL1 Peptide 
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Experiment  Line  Samples 
Binding to antigens 
A40~ x  10s: 
PSH3  PGLI  GIo 
1  Buffer only  24  14 
2  Normal  111  80 
3  Immune 2  98  1,468 
n 
4  Normal  --  --  315 
5  Immune 1  --  --  448 
6  Immune 2  --  --  449 
The rabbit was immunized with PGLI-KLH in CFA on days 0, 30, and 120, and was bled on day 70 
(immune 1) and 135 (immune 2). The antisera were assayed at  1:100 dilution. 
fractionated by electrophoresis under reducing conditions, and then transferred 
onto nitrocellulose paper.  After incubation with the antipeptide antibody and 
final development with ~25I-labeled  protein A, autoradiographs were prepared. 
Fig.  1 shows that the anti-PGL1  antiserum reacts with the kappa light chain of 
Glo, but not with the heavy chain of Glo, nor with the light chains of pooled 
human IgG. Thus, the anti-PGL1 displays antiidiotypic activity. 
Subsequently,  the specificity of the anti-PGL1  antiserum against a  panel of 
human IgM-RF  was examined by the immunoblot method. Fig.  2  shows that 
anti-PGL1  antibody reacts well with IgM-RF proteins Gar,  Glo, Got, and Pal, 
very weakly with Neu, Pay and Sie (data for Sie not shown), and not at all with 
IgM-RF Lay. Except for IgM-RF Pal, the amino acid sequences of the first CDR 
of the kappa chains of these IgM-RF have been reported (9, 13,  15,  16) and are 
shown in Table II. These results suggest that the majority of the polyclonal anti- 
PGL 1 antibodies recognize a  determinant associated with Val-Ser-Ser-Ser (resi- 
dues 28-31).  However, the anti-PGL1  antibodies also react with IgM-RF Got, 
which has Arg instead of Ser at position 29. One possible explanation is that the 
antigenic determinant for the majority of antiidiotype is Ser-Ser-Ser, that a lesser 
fraction recognizes Ser-Ser-Tyr, and that Val serves to enhance the binding of 
both antibodies through its hydrophobicity (see Discussion). Since both Ser and 
Tyr share the same functional hydroxyl group, the Ser-Ser-Tyr- and Ser-Ser- 
Ser-specific antibodies might be expected to have partial cross-reactivity. 
Anti-PGLI Antibody Reacts With Human IgG.  The epibody described by Bona 
et al.  (4)  was prepared against human  IgM-RF  Glo,  which contain the  PGL1 
sequence.  As  shown  in  Fig.  1,  the  PGLl-induced  antiidiotype  bound  to  the 
isolated gamma chains of human IgG. To assess the structural basis for this cross- 
reaction, two types of experiments were performed. First, the antibody-binding 
activity to the gamma chains was inhibited partially by the free PGL1 peptide in 
solution (Fig.  1).  Under the same conditions, an unrelated peptide, PSH3  (7), 
did not detectably inhibit the reaction (data not shown). However, it should be 
noted that the peptide inhibition of antibody binding to IgG gamma chain was 
not  as  significant  as  to  GIo  light  chain,  reaching  a  maximum  of  -70%  (as 326  AN  EPIBODY  INDUCED  BY  THE  SYNTHETIC  CDR  PEPTIDE 
FIGURE  1.  The  epibody  activity of the  anti-PGL1  antiserum.  10  tzg of each  sample  was 
loaded  into  each  slot.  The  polypeptides  were  transferred  after  sodium  dodecyl  sulfate- 
polyacrylamide gel electrophoresis, and  were incubated  with the  indicated antibodies (anti- 
PGL1 at  1:20 dilution, anti-human lg at 5 #g/ml) and inhibitor PGL1 (50 ~g/ml). 
suggested by the intensity of autoradiographs).  This suggests that some anti- 
gamma antibodies might have been induced nonspecifically or indirectly. 
Second, the PGLl-induced epibodies were enriched by affinity chromatogra- 
phy on a  human IgG column. As shown in Fig. 3,  the eluate from the human 
IgG column reacted with both the Glo light chain and IgG gamma chains, but 
not with IgG light chains. However, the binding to Glo light chain, but not to 
IgG gamma chain, was completely inhibited by the PGL1  peptide. Altogether, 
these results suggest that a portion of PGLl-induced antiidiotype reacted with 
intact IgG molecules, and that anti-PGL1 antiserum contains both epibody and 
anti-gamma antibody that was indirectly induced. 
Discussion 
An antiidiotype with "epibody" properties against the human monoclonal IgM- 
RF  Glo  was generated by immunization of a  rabbit  with a  synthetic peptide 
(PGL1),  corresponding to  the  first  CDR  of the  Glo  kappa  light  chain.  The 
antibody reacted specifically with both the PGL1  and the intact IgM-RF Glo. CHEN,  FONG,  HOUGHTEN,  AND  CARSON  327 
FIGURE 2.  The fine specificity of the anti-PGL1  antiserum.  Seven human monoclonal  IgM- 
RF were used at 10 ttg/slot, and were reacted with the anti-PGLl antiserum (1:20 dilution) or 
the anti-human lg (5. ~tg/ml). 
TABLE  II 
Amino Acid Sequences of the Kappa Chains of  Human Monoclonal IgM-RF Paraproteins  in 
the First CDR 
IgM-RF  Id 
Residue No. 
24  25  26  27  27A  28  29  30  31  32  33  34 
GIo*  + 
Gar  s  + 
Gotat  + 
LayO 
Neu*  __. 
Payat  + 
Sie  I  4- 
Arg  Ala  Ser  Gin  Ser  Val  Ser  Set  Ser  Tyr  Leu  Ala 
....................................................................... 
Arg  ......................... 
Gln  .(  )Asn  Val  Asn  Ala  -Asn 
Arg  ............... 
............................  Lys ................................... 
...........................................  Ash ............................ 
Residue number according to Kabat et al. (21). 
* Amino acid sequences were reported by Capra and Kehoe (9). 
at Amino acid sequences were reported by Ledford et al. (13). 
0 Amino acid sequences were reported by Klapper and Capra (15). 
I Amino acid sequences were reported by Andrews and Capra (16). 
When analyzed by the immunoblot method, the anti-PGL1  antibody recognized 
the  isolated  kappa  chains  of the  IgM-RF paraproteins  GIo,  Gar,  Got,  and  Pal, 
but not the kappa chains of IgM-RF Lay. The  anti-PGL1  antibody did not bind 
detectably to the heavy chains of any IgM-RF. The  binding of the antiserum  to 
the Glo kappa chain was completely inhibited by the free PGL1 peptide, but not 
by  a  control  peptide  (PSH3).  Thus,  the  synthetic  PGL1  peptide  induced  an 
antiidiotype against a  cross-reactive idiotype associated  with the kappa chains of 328  AN  EPIBODY  INDUCED  BY  THE  SYNTHETIC  CDR  PEPTIDE 
FIGURE  3.  The human IgG affinity-isolated, anti-PGLl antibodies consisted of two sets: the 
epibody and the anti-lgG antibody.  Nitrocellulose paper with polypeptides were  incubated 
with antibodies (0.5 ttg/ml) and the indicated amount of inhibitor PGL1. 
several human IgM-RF autoantibodies. The molecular basis of this cross-reactive 
idiotype is defined by the PGL1 amino acid sequence. 
In our initial observations of the anti-PGL 1 antibody, we were surprised and 
disappointed by its binding with the gamma chain of the pooled human  IgG. 
However,  the epibody described  by  Bona et al.  (4)  prompted us to study the 
exact specificities of this peculiar antiserum. 
The epibody was defined (4) as an antiidiotype that reacted with the antigen 
of the idiotype-bearing antibody. Experiments were done to demonstrate that a 
portion of the PGL 1-induced 'polycional' antiidiotype did react additionally with 
human IgG, as a  regular antibody reacts with its antigen. Fig.  1 shows that the 
binding  of  PGLl-induced  antiidiotype  with  IgG  gamma  chain  was  partially 
inhibited  by  PGL 1,  suggesting that  there  are  at  least  two sets of anti-gamma 
components in  the polyclonal antiserum,  and that only one set recognizes the 
PGL 1-associated epitope on the IgG gamma chain. Fig. 3 shows that both sets of 
anti-gamma antibodies  in  the  serum  can  be  adsorbed  by,  and  eluted  from,  a 
human IgG column, demonstrating that they react with intact IgG molecules. In 
addition,  the  anti-PGL1  antibodies,  previously  adsorbed  with  a  human  IgG 
column, still reacted with the Glo light chains (data not shown). In contrast, the 
human IgG column eluate of anti-PGL1  antisera  that was subsequently passed 
through a  PGL1  column reacted only with IgG, and not Glo (data not shown). 
By  pooling  these  data,  the  anti-PGL1  antibodies  can  be  classified  as  follows 
(Table Ill):  (a) conventional antiidiotype that reacts with GIo light chain only, 
and whose antibody reactivity is completely inhibited by PGL1; (b) epibody that 
reacts  with  both  Gio  light  chain  and  IgG,  and  whose  antibody  reactivity  is 
inhibitable by PGL1;  and (c) anti-IgG antibody that reacts with IgG only, and 
whose binding is not inhibitable by PGL1. 
It should be pointed out that the epibody constitutes only a very small portion 
of the overall anti-PGL1  antibodies,  that its binding to the separated Glo light 
chain and IgG gamma chain is of low affinity, and that the binding to intact Glo CHEN, FONG, HOUGHTEN, AND  CARSON  329 
TABLE III 
Three Components in the Anti-PGLI Antiserum 
Antibody 
Reactivity  with: 
GIo  GIo light  IgG  IgG heavy  PGL1 
Anti-GIo, conventional  +  +  -  -  + 
Epibody  +  +  +  +  + 
Anti-lgG  -  -  +  +  - 
Inhibition of binding by PGLI  * 
Anti-GIo, conventional  +at  +  NA  !  NA  + 
Epibody  +  +  -  +  + 
Anti-lgG  NA  NA  -  -  NA 
* Inhibition of binding to intact protein was done by ELISA  (data not shown). 
at PGL1 at 500 #g/ml gave about 10% inhibition. 
i Not applicable. 
and intact IgG is of even lower affinity. The anti-IgG component was induced 
indirectly, possibly through the immune network or other unknown mechanisms. 
Other than the original description by Bona et al. (4), the existence of  epibodies 
has not been confirmed, so their biological significance could not be investigated. 
The current paper confirms independently the existence of  epibodies. Moreover, 
it is likely that the structural basis of the epibody described here is the Ser-Ser- 
Ser sequence shared  by the reactive  IgM-RF (Glo and Gar) and human IgG 
molecules [residue  195-197,  number according to  Kabat et al.  (21)].  This is 
based on the following: (a) Anti-PGL1 recognizes mainly a determinant consist- 
ing of VaI-Ser-Ser-Ser  (Fig.  2);  (b) antiidiotypes, induced by a  similar peptide 
PSL 1 (which corresponds to the first CDR of Sie light chain and is identical to 
PGL 1 except for having Asn instead of Ser at position 9),  did not react with 
human IgG (unpublished data); (c) anti-PGL1 reacted with the F(ab')2, but not 
Fc, of the human. IgG (data not shown);  (d) three of six  gamma chains with 
known sequences (Eu, Nie, and IgG G4) have Ser-Ser-Ser at position 195-197, 
while neither one of two p chains (Gal and Ou) have Ser-Ser-Ser sequence. 
Numerous  investigations using dextran  and  homopolymers of amino acids 
have concluded that the antibody-combining site can accommodate a  hexasac- 
charide or tetrapeptide (22).  In addition, analysis of the antigenic determinant 
size of the protein antigens revealed that a determinant consisted of a pentapep- 
tide or a  tetrapeptide  (reviewed  in  23).  Moreover,  in  the  case of C-terminal 
pentapeptide of tobacco masaic (TMV) virus,  Leu-Asp-Ala-Thr-Arg, the Leu- 
Asp could be replaced by N-octanoyl (24).  This suggested that the anti-TMV 
antibodies recognized specifically the tripeptide Ala-Thr-Arg, while the Leu-Asp 
enhanced the antibody binding by providing hydrophobicity. Thus, the loss of 
idiotype in the RF Pay can be explained by the decreased hydrophobicity, due 
to the Val ~  Lys substitution at position 28.  Similarly, it is interesting to note 
that IgG has Vai-Pro at the N-terminal to Ser-Ser-Ser (21). 
Summary 
Recently, an antiidiotype to human monocional IgM anti-IgG autoantibodies 
(rheumatoid factors) was  found to  react also  with  human  IgG.  This peculiar 330  AN  EPIBODY INDUCED BY  THE SYNTHETIC  CDR  PEPTIDE 
antiidiotype  was  called  an  'epibody'.  We  describe  the  induction  of a  similar 
epibody by immunization with a synthetic peptide (corresponding to one hyper- 
variable  region  of  the  IgM-RF  Glo).  The  results  confirm  the  existence  of 
epibodies, and provide the possible molecular basis of the epibody phenomenon. 
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